SCHEMBL2384705

SCHEMBL2384705

COc1cccc2nc(-c3cc(Br)cnc3N)oc12

nearest known ligand 0.44

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 2/20 0.44
ALDH1A1 P00352 2/20 0.44
MAPT P10636 1/20 0.44
MET P08581 4/20 0.41
GRK5 P34947 1/20 0.41
C1R P00736 1/20 0.41
RPS6KA2 Q15349 1/20 0.40
PDE4C Q08493 3/20 0.39
SHMT2 P34897 1/20 0.38
ESR1 P03372 1/20 0.38
ESR2 Q92731 1/20 0.38
RAB9A P51151 1/20 0.38
ELANE P08246 1/20 0.37
DCPS Q96C86 1/20 0.37
ATR Q13535 1/20 0.37
MAOB P27338 1/20 0.37
PTGS2 P35354 1/20 0.37
NPC1 O15118 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2385455 0.81 MET (0.41) KDM4EMAPTMETGRK5C1R
SCHEMBL2387190 0.81 CETP (0.44) KDM4EMAPTMETGRK5ESR2
SCHEMBL2386233 0.81 F2RL3 (0.41) KDM4EALDH1A1MAPTMETSHMT2
SCHEMBL2388524 0.80 SGMS2 (0.49) KDM4EALDH1A1MAPTGRK5C1R
SCHEMBL2386305 0.79 ESR1 (0.40) KDM4EALDH1A1METGRK5ESR1
SCHEMBL2384707 0.78 MET (0.63) KDM4EALDH1A1MAPTMETRAB9A
SCHEMBL2386539 0.76 MAPT (0.38) KDM4EALDH1A1MAPTC1RPDE4C
SCHEMBL2386739 0.74 ESR2 (0.39) MAPTMETGRK5ESR1ESR2
SCHEMBL16974099 0.74 FYN (0.49) ALDH1A1SHMT2
SCHEMBL29858095 0.74 FYN (0.49) ALDH1A1SHMT2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8017611-B2 Pyridine and pyrazine derivatives -083 ASTRAZENECA AB (SE) 2011-09-13 US disclosed
EP-2215085-B1 PYRIDINE AND PYRAZINE DERIVATIVES USEFUL IN THE TREATMENT OF CELL PROLIFERATIVE DISORDERS ASTRAZENECA AB (SE) 2011-09-07 EP disclosed
EP-2215085-A2 PYRIDINE AND PYRAZINE DERIVATIVES USEFUL IN THE TREATMENT OF CELL PROLIFERATIVE DISORDERS AstraZeneca AB (SE) 2010-08-11 EP disclosed
US-20090118305-A1 PYRIDINE AND PYRAZINE DERIVATIVES - 083 ASTRAZENECA AB (SE) 2009-05-07 US disclosed
WO-2009053737-A2 PYRIDINE AND PYRAZINE DERIVATIVES USEFUL IN THE TREATMENT OF CELL PROLIFERATIVE DISORDERS ASTRAZENECA AB (SE) 2009-04-30 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090118305-A1 PYRIDINE AND PYRAZINE DERIVATIVES - 083 MKI67, CCND3, CCND1 KDM4E 2374/4885ALDH1A1 802/4885MAPT 2946/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.